Updated on 14 October 2015
University College London (UCL) and Japan's Takeda Pharmaceutical Company Limited have signed a new research collaboration to identify and validate novel target genes for the treatment of neurodegenerative disease.
This collaboration will focus on mechanistic approaches for the identification of genes or signaling pathways that modify neurodegenerative disease processes affecting neuronal health (for example motor neurone disease (MND or ALS), Huntington's disease and Parkinson's disease).
The collaboration, which includes support from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, will initially run for a three-year period. It will be carried out by Takeda Cambridge Limited, Takeda's research unit based in Cambridge, UK. It is said to be one of the largest university partnerships formed by Takeda in the United Kingdom.
Dr. Tetsuyuki Maruyama, General Manager of Takeda's Pharmaceutical Research Division said, "At Takeda, we work with partners to accelerate innovation. We are looking forward to collaborating with UCL's world-class researchers. This cooperation will help us to identify and validate novel therapeutic pathways in central nervous system diseases, which is one of Takeda's core therapeutic areas - ultimately leading to new treatments for patients suffering from neurodegenerative disorders."
UCL is a leading university in CNS research especially in the field of neurodegeneration and rare neurological disorders. UCL's Institute of Neurology is a centre of significant investment for dementia research with a highly engaged and interactive faculty.
Takeda Cambridge is a subsidiary of Takeda Pharmaceutical Company Limited, a research-based global pharmaceutical company. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Takeda Cambridge is Takeda's research unit in the UK focused on target identification and drug discovery, with CNS being one of its key focus areas.